ALNY vs SEPN: fair value comparison
Alnylam Pharmaceuticals, Inc. and Septerna, Inc. · Updated 2026-10-19
ALNY is still awaiting a full valuation verdict under our six-validated-windows standard. SEPN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, SEPN currently ranks higher by quality score.
| ALNY | SEPN | |
|---|---|---|
| Verdict | Awaiting full valuation | No estimate yet |
| Last price | $231.83 | $36.35 |
| 12-month range | $205.48–$481.59 | $18.10–$48.19 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #22 of 301 Healthcare | #21 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | — |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| 52-week position | The bottom quarter | The upper-middle quarter |
Full single-stock breakdowns: ALNY fair value analysis · SEPN fair value analysis